{
    "root": "4b7cbcd3-7192-43cf-bd16-98bc8ed95645",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lo Loestrin Fe",
    "value": "20250307",
    "ingredients": [],
    "indications": "lo loestrin\u00ae fe indicated women prevent pregnancy [ ( 14 ) ] . efficacy lo loestrin fe women body mass index ( bmi ) > 35 kg/m2 evaluated .",
    "contraindications": "take one tablet mouth time every day 28 days ( 2.1 ) take tablets order directed blister pack ( 2.1 )",
    "warningsAndPrecautions": "lo loestrin\u00ae fe ( norethindrone acetate ethinyl estradiol tablets , ethinyl estradiol tablets ferrous fumarate tablets ) available blister cards ( dispensers ) containing 28 tablets : ndc 0430-0420-14 cartons 5 blister cards ( dispensers ) ndc 0430-0420-60 cartons 30 blister cards ( dispensers ) blister card ( 28 tablets ) contains following order : 24 blue , round tablets ( active ) imprinted \u201c wc \u201d one side \u201c 421 \u201d containing 1 mg norethindrone 10 mcg ethinyl estradiol 2 white , hexagonal tablets ( active ) imprinted \u201c wc \u201d one side \u201c 422 \u201d containing 10 mcg ethinyl estradiol 2 brown , round tablets ( non-hormonal placebo ) imprinted \u201c wc \u201d one side \u201c 624 \u201d containing 75 mg ferrous fumarate",
    "adverseReactions": "lo loestrin fe contraindicated females known develop following conditions : high risk arterial venous thrombotic diseases . examples include women known : \u2022 smoke , age 35 [ boxed warning ( 5.1 ) ] \u2022 deep vein thrombosis pulmonary embolism , past [ ( 5.1 ) ] \u2022 cerebrovascular disease [ ( 5.1 ) ] \u2022 coronary artery disease [ ( 5.1 ) ] \u2022 thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] \u2022 inherited acquired hypercoagulopathies [ ( 5.1 ) ] \u2022 uncontrolled hypertension [ ( 5.5 ) ] \u2022 diabetes mellitus vascular disease [ ( 5.7 ) ] \u2022 headaches focal neurological symptoms migraine headaches without aura age 35 [ ( 5.8 ) ] current diagnosis , history , breast cancer , may hormone-sensitive [ ( 5.2 ) ] liver tumors , benign malignant , liver disease [ ( 5.3 ) ] undiagnosed abnormal uterine bleeding [ ( 5.9 ) ] hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir , due potential alt elevations [ ( 5.4 ) ] .",
    "indications_original": "Lo Loestrin\u00ae Fe\u00a0is indicated for use by women to prevent pregnancy [\n                     see \n                     \n                        Clinical Studies (14)\n                     \n                     ].\u00a0\u00a0\n                  The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of >\u00a035 kg/m2 has not been evaluated.",
    "contraindications_original": "Take one tablet by mouth at the same time every day for 28 days\u00a0( 2.1 ) Take tablets in the order directed on the blister pack ( 2.1 )",
    "warningsAndPrecautions_original": "Lo Loestrin\u00ae Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) is available in blister cards (dispensers) containing 28 tablets:\u00a0\n                        NDC 0430-0420-14 \n\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\t\n\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\tCartons of 5 blister cards (dispensers) \n                        NDC 0430-0420-60 \n\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\t\n\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\tCartons of 30 blister cards (dispensers)  \n                        Each blister card (28 tablets) contains in the following order:\n                        \n                           24 blue, round tablets (active) imprinted with \u201cWC\u201d on one side and \u201c421\u201d on the other and each containing 1 mg norethindrone and 10 mcg ethinyl estradiol\n                           \n                           2 white, hexagonal tablets (active) imprinted with \u201cWC\u201d on one side and \u201c422\u201d on the other and each containing 10 mcg ethinyl estradiol\n                           \n                           2 brown, round tablets (non-hormonal placebo) imprinted with \u201cWC\u201d on one side and \u201c624\u201d on the other and each containing 75 mg ferrous fumarate",
    "adverseReactions_original": "Lo Loestrin Fe\u00a0is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:\u2022\u00a0Smoke, if over age 35\u00a0[see \n                        \n                           Boxed Warning\n                        \n                        \u00a0and\u00a0\n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have deep vein thrombosis or pulmonary embolism, now or in the past\u00a0[see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have cerebrovascular disease [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have coronary artery disease\u00a0[see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)\u00a0[see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have inherited or acquired hypercoagulopathies\u00a0[see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ]\n                        \u2022\u00a0Have uncontrolled hypertension\u00a0[see \n                        \n                           Warnings and Precautions (5.5)\n                        \n                        ]\n                        \u2022\u00a0Have diabetes mellitus with vascular disease\u00a0[see \n                        \n                           Warnings and Precautions\u00a0(5.7)\n                        \n                        ]\n                        \u2022\u00a0Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35\u00a0[see \n                        \n                           Warnings and Precautions\u00a0(5.8)\n                        \n                        ]\n                        \n                     \n                     Current diagnosis of, or history of, breast cancer,\u00a0which may be hormone-sensitive\u00a0[see \n                        \n                           Warnings and Precautions (5.2)\n                        \n                        ]\n                        \n                     \n                     Liver tumors, benign or malignant, or liver disease\u00a0[see \n                        \n                           Warnings and Precautions (5.3)\n                        \n                        ]\n                        \n                     \n                     Undiagnosed abnormal uterine bleeding [see \n                        \n                           Warnings and Precautions (5.9)\n                        \n                        ]\n                        \n                     \n                     Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations [see \n                        \n                           Warnings and Precautions (5.4)\n                        \n                        ]."
}